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Abstract
Chikungunya virus (CHIKV) is known to cause sporadic or explosive outbreaks. However, little is known about the endemic
transmission of CHIKV. To ascertain the endemic occurrence of CHIKV transmission, we tested blood samples from patients
with a non-dengue febrile illness who participated in a prospective cohort study of factory workers in Bandung, Indonesia.
From August 2000 to June 2004, and September 2006 to April 2008, 1901 febrile episodes occurred and 231 (12.2%) dengue
cases were identified. The remaining febrile cases were evaluated for possible CHIKV infection by measuring anti-CHIKV IgM
and IgG antibodies in acute and convalescent samples. Acute samples of serologically positive cases were subsequently
tested for the presence of CHIKV RNA by RT-PCR and/or virus isolation. A total of 135 (7.1%) CHIKV infections were
identified, providing an incidence rate of 10.1/1,000 person years. CHIKV infections were identified all year round and
tended to increase during the rainy season (January to March). Severe illness was not found and severe arthralgia was not a
prominently reported symptom. Serial post-illness samples from nine cases were tested to obtain a kinetic picture of IgM
and IgG anti-CHIKV antibodies. Anti-CHIKV IgM antibodies were persistently detected in high titers for approximately one
year. Three patients demonstrated evidence of possible sequential CHIKV infections. The high incidence rate and
continuous chikungunya cases in this adult cohort suggests that CHIKV is endemically transmitted in Bandung. Further
characterization of the circulating strains and surveillance in larger areas are needed to better understand CHIKV
epidemiology in Indonesia.
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Introduction
Chikungunya virus (CHIKV) is an arthropod-borne virus
belonging to the genus Alphavirus in the family Togaviridae [1].
CHIKV causes an acute illness similar to dengue, characterized by
fever, headache, nausea, vomiting, abdominal pain, myalgia, rash
and arthralgia [2]. Arthralgia of the large joints may be severe and
long lasting [3]. CHIKVwas first identified in Tanzania in 1952 [4].
Over the next decades, it remained a relatively rare disease causing
mostly small outbreaks in both Africa and Asia [2]. This changed
dramatically after a mutation in the CHIKV E1 glycoprotein gene
(A226V) occurred. This mutation enhanced the infectivity of the
virus and its transmission by Aedes albopictus [5]. In 2005, the mutated
CHIKV spread from the Indian Ocean where it produced large
epidemics in India, Southeast Asia and Italy [6–9].
CHIKV in Africa is predominantly maintained in an inter-
epidemic sylvatic cycle in which the virus resides in wild primates
and mosquitoes such as Aedes furcifer-taylori and Aedes africanus. In
Asia, Aedes aegypti, an anthrophophilic mosquito that lives in
proximity with humans, has been the most significant vector [10].
In contrast, for the mutated CHIKV that caused the recent
epidemic in the Indian Ocean, Aedes albopictus is the main vector
[5].
In Indonesia, chikungunya was first reported in 1982 in East
Sumatera. It then spread to other islands including Java,
Kalimantan, Bali, Flores and Sulawesi [11]. After a hiatus of 15
years, sporadic outbreaks were reported simultaneously in several
provinces on the island of Java in 2000–2002 [11]. Since then,
clusters of cases have been reported sporadically from several
provinces although the total number of cases reported has never
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exceeded 5,000 per year [12,13]. This number should be
interpreted with caution, however, because similarities in symp-
toms between dengue and chikungunya [2] and logistic constraints
in viral diagnostics in Indonesia [14] may have resulted in a gross
underestimation of the incidence of chikungunya [15]. To better
define the disease burden of chikungunya, active surveillance
during non-outbreak periods is necessary. However, to our
knowledge, no such studies have been conducted elsewhere.
Therefore, to determine CHIKV transmission during inter-
epidemic periods and the epidemiology of CHIKV infections in
Indonesia, we analyzed the demographic, clinical and virological
data collected from non-dengue acute febrile patients participating
in a prospective adult cohort dengue study that was conducted in
Bandung, West Java, Indonesia from 2000–2004 and 2006–2008.
Materials and Methods
Study design
This study was a part of ‘‘An epidemiology study of dengue and
dengue hemorrhagic fever in adults’’, approved by the Institu-
tional Review Board of NAMRU#2, Jakarta (IRB#30855 and
N2.2006.0001) and the National Institute of Health Research and
Development (NIHRD), Ministry of Health, Indonesia (KS
02.02.2.1.2181, KS 02.01.2.1732 and KS.02.01.2.1.2776) in
compliance with all U.S. Federal Regulations governing the
protection of human subjects. Details of the study design are
described elsewhere [16]. In brief, it was a textile factory-based
prospective cohort study conducted in Bandung, West Java,
Indonesia, a city that has more than 2 million inhabitants. The
study was conducted in two phases, 2000–2004 and 2006–2008.
Phase 1 was carried out in factories A and B, and phase 2 was
carried out in factories A and C. A cohort of 2978 volunteers was
maintained during the first phase and 2726 during the second
phase with 44.5% of volunteers from cohort 1 also participating in
cohort 2. All volunteers gave written informed consent prior to
enrollment. During enrollment, demographic and health status
data were obtained and baseline blood specimens were collected.
On a quarterly basis, surveys were conducted, and blood samples
were taken to examine the volunteers’ dengue serological status.
Between each survey, volunteers who experienced fever came to
the factory clinic where a clinical evaluation was performed and
acute and convalescent (at least 7 days apart) blood specimens
were collected. Specimens were immediately tested for dengue
using a battery of dengue diagnostic assays [16]. Patients were
advised to be hospitalized at the discretion of the attending
physician or if their platelet count was less than 150,000/mm3.
Once a dengue infection was excluded, the samples were tested for
evidence of CHIKV infection as described below. During phase 1
of the study, volunteers were not questioned about arthralgia and
data concerning arthralgia was obtained when this symptom was a
chief or other complaint during their illness or during post-illness
serosurveys. During phase 2 of the study, volunteers were
specifically asked about arthralgia. There were no other differ-
ences in symptom ascertainment between phase 1 and 2.
Diagnosis of CHIKV infections
Convalescent sera from febrile volunteers who had been
excluded as dengue cases were first tested to detect CHIKV
IgM antibodies using enzyme-linked immunosorbent assay
(ELISA). When positive, paired acute and convalescent sera were
further tested for CHIKV IgM and IgG antibodies using an
ELISA, and acute sera were processed for viral isolation and/or
tested by RT-PCR to detect CHIKV genomes. CHIKV infection
was confirmed when CHIKV genome or virus was detected, or
when either seroconversion or a four-fold rise in titers of anti-
CHIKV IgM and IgG antibodies was detected.
CHIKV IgM and IgG ELISA
Serum samples were assayed for the presence of IgG and IgM
antibodies against CHIKV using ELISA as previously described
[14,17]. The CHIK antigen was prepared from Vero E6 cell
culture infected with CHIKV 23574, an Asian lineage virus
isolated from CHIK infected patient. Uninfected Vero E6 cell
culture was used as negative antigen. For detection of CHIK IgM,
96- well microtiter plates (Immulon 2, Dynex Technologies,
Chantilly, VA) were coated with anti-human IgM antibodies
(Kirkegaard and Perry, Gaithersburg, MD). Excess antibodies
were washed with 0.1% Tween Phosphate-buffered saline (PBS).
Serum was diluted 1:100 in dilution buffer (PBS, 0.1% Tween-20,
and 5% skim milk), and incubated at 37uC for one hour. Plates
were then washed and antigens were added. After incubation,
anti-CHIK hyperimmune mouse ascitic fluid and horseradish
peroxidase-conjugated anti-mouse IgG (Kirkegaard and Perry,
Gaithersburg, MD) were used to detect IgM specific to CHIKV.
ABTS substrate was allowed to react for one hour and absorbance
was determined at 415 nm. For the detection of CHIK specific
IgG antibodies, a 96-well microtiter plate was coated directly with
cell lysate antigens diluted in PBS. Horseradish peroxidase
conjugated mouse anti-human IgG Fc (Kirkegaard and Perry,
Gaithersburg, MD), and ABTS were used to detect bound
antibody. The adjusted optical density value (OD) for each sample
was determined by subtracting the OD obtained with the negative
antigen from the OD obtained using the CHIK antigen. A sample
was considered positive if its OD value exceeded the mean plus
three standard deviations of the normal control sera. The endpoint
of antibody titers was determined by testing ELISA-positive
samples at serial two-fold dilutions starting from 1:100. The
highest dilution showing a positive result was considered the
endpoint titer. It has previously been established that our CHIK
immunoassay does not show immunoreactivity against Ross River
virus [17].
Author Summary
Chikungunya is one of the neglected diseases. It has only
attracted attention during outbreaks, in particular, the
large epidemics in the Indian Ocean in 2005–2006. To our
knowledge, there has never been any surveillance to
determine the transmission of this virus among humans in
non-outbreak settings. Such surveillance is particularly
important because it will provide a better estimate of the
disease burden and valuable information on how this virus
is maintained outside outbreaks. Our study, conducted
between 2000 and 2008 in Bandung, West Java, Indonesia,
yielded several important findings: 1. Chikungunya is an
important cause of fever among adults in Bandung,
Indonesia. 2. The clinical symptoms are mostly mild and
short lasting. 3. In addition to previously described
epidemiological features involving episodic outbreaks, it
is also continuously transmitted throughout the year. 4. A
few patients may have experienced more than one
chikungunya virus infection. 5. Only the Asian genotype
was found and not the East Central South African
genotype that was responsible for the 2005 outbreak in
the Indian Ocean. 6. The persistence of IgM for a long
period after illness may complicate the interpretation of
laboratory results.
Endemic Chikungunya in Bandung, Indonesia
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The kinetics of IgM and IgG antibodies to CHIKV were
analyzed using specimens from the first nine patients who had
complete serial quarterly serosurvey sera for two years.
Virus isolation and CHIKV RT-PCR
Acute sera from cases diagnosed by seroconversion or a four-
fold increase of anti-CHIKV IgM and IgG antibody titers were
processed for virus isolation and analysis by RT-PCR. The
methods used to perform these assays have been described
previously [14,17]. For virus isolation, serum samples were diluted
1:10 in PBS and applied to confluent monolayers of C6/36 cells in
24-well culture plates (Corning, New York). The plates were
centrifuged at 400g for 45 minutes and then 1 ml of medium
(MEM) added. The plates were then incubated at 30uC for 14 days
and observed daily for evidence of cytopathic effects (CPE). At the
end of 14 days or upon recognition of CPE, cells were removed
from the plates and evaluated for the presence of virus by standard
immunofluorescence assay using anti-CHIK hyperimmune mouse
ascitic fluid and FITC conjugated anti-mouse IgG (Kirkegaard
and Perry, Gaithersburg, MD). For RT-PCR, viral RNA was
extracted using a QIAamp Viral RNA Isolation Kit (QIAGEN,
Hilden, Germany). RNA was then used in a nested RT-PCR assay
using JM1 (59 GCAGAC GCAGAGAGGGCCAG 39; bp 1,201 to
1,220) and JM2 (59 CGTGCTGCAAGG TAGTTCTC 39; bp
1,440 to 1,421) primers. A second nested PCR was performed
using the product from the first reaction and primers JM3 (59
GCTATTTGTAAGAAC GTCAG 39; bp 1,221 to 1,240) and
JM4 (59 TACCGTGCTGCGGTCGGGAA 39; bp 1,420–1,401).
Amplified PCR products were resolved by electrophoresis on a 2%
agarose gel and visualized using ethidium bromide.
Genomic sequencing
Sequencing of the structural polyprotein coding region of 20
chikungunya virus isolates was performed (Genbank accession
numbers: KC879559–KC879578), using primers that were
previously described [18]. Cycle sequencing reactions were
conducted using the BigDye 3.3 Terminator Ready Reaction
mix (Applied Biosystems, Carlsbad, California). Cycle sequencing
was performed at least twice per primer per sample. The
sequencing products were separated from unbound dye using
BigDye X-Terminator (Applied Biosystems) and analyzed on an
ABI 3130 XL Genetic Analyzer (Applied Biosystems).
Sequence data analysis was performed using Sequencher 3.1
(Genecodes, Ann Arbor, MI) with the default parameters to
improve the overall sequence quality. ClustalX 2.0.9 [19] was used
to perform multiple sequence alignment. The alignment param-
eters used were 50 points penalty for gap opening, 2 point penalty
for gap extension, and all gaps were reset before each alignment.
Several reference sequences were used for the alignment: six Asian
genotype viruses (among them a vaccine strain), five East/
Central/South African (ECSA) genotype viruses, and one West
African genotype virus. After obtaining the alignment, excess
sequence (outside the coding region for the structural proteins) was
discarded. The phylogenetic tree was constructed using the
neighbor-joining method [20] with MEGA4 software [21]. The
distance model used was the Kimura 2 parameter model to correct
for multiple substitutions and to account for unequal transition/
transversion ratio. The tree was constructed with 1000 bootstrap
replicates.
Statistical analysis
Descriptive data (mean age and standard deviation) were
analyzed using STATA version 9.0 (StataCorp 2005, College
Station, TX).
Results
Study population
A total of 4380 volunteers were enrolled into the study,
consisting of 1324 volunteers who joined from the beginning of
this study (August 2000), 1654 who discontinued their participa-
tions after the first phase (June 2004) and 1402 new enrollees in the
second phase (September 2006 to April 2008). The mean (SD) age
and age range of volunteers at enrollment were 37.1 (67.7) and 18
to 66 years old. A higher proportion of the study population was
male (ratio 1.85: 1).
Chikungunya cases
The proportion and incidence rate of chikungunya
cases. A total of 1431 acute febrile episodes (AFE) occurred
among 2978 volunteers in the first phase of the study, which lasted
for 47 months. CHIKV infection was identified in 96 (6.7%) of
these AFE, yielding a yearly incidence rate of 10.1 per 1,000
persons. During the second phase of the study in which 2726
volunteers were followed for 20 months, 39 chikungunya cases
were diagnosed among 470 AFE, resulting in a slightly higher
percentage and incidence rate (8.3% and 10.3/1,000 persons/
year). In total, the percentage and incidence rate were 7.1% and
10.1/1,000 (persons/year), respectively. The number of chikun-
gunya cases per month over the years and the total number of
cases per year are shown in figure 1. The number of cases
remained relatively stable over the years, except for two peaks in
early 2004 and 2008, when chikungunya accounted for 11.2% and
11.7% of the AFE. In contrast, no cases were found in the second
half of 2000 and only one case in the last four months of 2006.
Cases were found almost all year round, however November had
the lowest number of cases and cases tended to increase during the
wet season from January to March. Chikungunya cases resided
throughout the city without apparent clustering by residence
although the majority of cases were from the subdistricts near the
factories where most workers lived (data not shown).
Diagnosis of CHIKV infections, antibody kinetics and
virus sequencing. In 69 (51.1%) of the 135 CHIKV infections,
the diagnosis of acute CHIKV infection was confirmed by positive
RT-PCR, viral isolation and serology results. In 47 (34.8%) cases
the diagnosis was confirmed by positive RT-PCR and serology
results, while 19 (14.1%) cases only had serological evidence of
CHIK infection. Of these 19 cases, 10 were negative for RT-PCR
and isolation, eight did not have RT-PCR performed and one did
not have viral isolation performed due to an insufficient volume of
serum.
Post-illness sera from nine patients, who had serial specimens
taken during serosurveys over two years, were tested to evaluate
the kinetics of CHIKV IgM and IgG antibodies (figure 2). These
nine patients did not have any anti-CHIKV IgM or IgG
antibodies in their pre-illness samples and IgM antibodies were
undetectable in the acute specimen of seven of these patients. The
two patients in which IgM was detectable in the acute sample
came to the clinic later in disease on day five and seven of illness
and had anti-CHIKV IgM titers of 400 and 3200 respectively. In
convalescent and late convalescent sera, titers increased strongly,
followed by a subsequent slow decline thereafter. In most patients
(8/9), IgM antibodies were detectable for a long period after acute
infection, ranging from 5–22 months. In one patient, the IgM titer
became undetectable three months after the onset of illness. The
demographic and clinical findings of this patient did not differ
from the rest. IgG antibodies were not detected in 8 of 9 acute
samples while one sample had a titer of 100. In convalescent sera,
which were collected 2–3 weeks after onset of fever, IgG antibodies
Endemic Chikungunya in Bandung, Indonesia
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were detected at low titers (200–800) in 7 of 9 patients and at high
titers (1600 and 3200) in two patients. IgG titers peaked (6400 to
1:25600 dilution) at 3–4 months after the onset of illness, then
decreased slightly and remained stable at high titers (1600 to 3200)
for two years after illness.
CHIKV could be isolated from specimens collected until day 4
of the illness whereas RNA was detectable by RT-PCR until 6
days post illness onset. Sequencing analysis was performed on 20
isolates from the first and second phases of the study. All isolates
had alanine at position 226 in the E1 gene. Nucleotide similarity
between these isolates was .99.4%, and amino acid similarity was
.99.7%. A phylogenetic tree was constructed based on 1320 bases
of the structural polyprotein coding region. All samples sequenced
from this study clustered together and belong to the Asian
genotype (figure 3).
Clinical manifestations. Most patients came to the clinic
on day two or three of fever (57 and 56 patients out of 135
patients, respectively). Table 1 lists their clinical manifestations.
The most frequent were myalgia (92.5%), headache (88.8%),
and arthralgia (38.9% during the first phase and 87.2%, during
the second phase). Among 34 patients with arthralgia in the
second phase of the study, the most commonly involved joints
were the knees (85.3%), shoulders (64.7%), smaller joints and
elbow (58.8%). The initial working diagnoses made by clinicians
during enrollment at the health centers in cases with laboratory
confirmed chikungunya included undifferentiated fever (71.1%),
dengue fever (12.6%), upper respiratory tract infection (8.1%),
typhoid fever (3%), chikungunya fever (1.5%), measles and
gastroenteritis (each 0.7%). Clinical manifestations were mostly
mild and no severe cases occurred. Seven patients (5.2%) were
hospitalized because their platelet level was under 150,000/
mm3, five from the first cohort and two from the second cohort.
As chikungunya diagnostic assays were not available at the
hospitals, discharged clinical diagnoses were acute viral infection
and dengue fever in 5 and 2 patients, respectively. Approxi-
mately one third (32.6%) of patients did not skip work at all,
36.3% were absent for 1 to 3 days, 19.3% for 4 to 6 days and
11.9% for more than a week. The average number of days
absent was 2.7 days.
Evidence of possible recurrent CHIKV infections
We identified two patients with a laboratory confirmed acute
CHIKV infection in whom serology results on a blood sample
collected three months before illness suggested a previous
CHIKV infection. In the first volunteer, an acute CHIKV
infection was confirmed by RT-PCR, virus isolation and
serology. In the second patient, CHIKV infection was confirmed
by RT-PCR and serology (Table 2). Both patients reported fever,
headache and myalgia, but no arthralgia. We also identified a 34-
year-old male for whom we had evidence of two possible
chikungunya episodes during our study. The first episode was in
June 2002 when an acute CHIKV infection was confirmed by
positive RT-PCR, virus isolation and IgM and IgG sero-
conversion; the second episode occurred four and half years
later and was confirmed by a four-fold rise in IgM (Table 2). For
both episodes, dengue was excluded as all dengue diagnostic tests
were negative. Clinical manifestations in both episodes were
similar, including high fever, headache, sore throat, malaise and
bilateral arthralgia. Results from hematology and chemistry tests
did not show pathognomonic findings.
Figure 1. Monthly, annual total number and annual incidence rates for laboratory confirmed chikungunya (CHIK) cases. The number
of CHIK cases per month is represented by skinny black rectangles. The total number of cases for a year is indicated by light gray rectangles and the
incidence rate for a year is indicated by dark gray rectangles. The rectangles representing annual data are placed at the midpoint (July) for their
respective year.
doi:10.1371/journal.pntd.0002483.g001
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Figure 2. Immunokinetics of anti-chikungunya virus IgM (top) and IgG (bottom). The mean +/2 SD titer for each timepoint (W=weeks,
M=months) after illness onset. N = the number of samples for a given timepoint.
doi:10.1371/journal.pntd.0002483.g002
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Discussion
Our studies, conducted between 2000 and 2008 in a large town
in West Java, Indonesia, revealed several important epidemiolog-
ical findings, including: 1. Among adults, CHIKV was an
important cause of acute febrile illness. 2. CHIKV infections did
not occur in epidemics as commonly reported, but were found
throughout the year. 3. The clinical symptoms of CHIKV
infection in this cohort were mostly mild and short-lived. 4.
CHIKV infections were caused by the Asian genotype and not by
the mutated East Central South African strain (ECSA), although
only a limited number of samples were genotyped. 5. The
persistence of IgM for a long period after illness may complicate
the interpretation of laboratory results, and finally 6. We found
evidence of possible recurrent CHIKV infections. We have
previously reported an incidence rate of acute dengue of 18.1
Figure 3. Phylogenetic analysis of the CHIKV isolates. Neighbor-joining tree of the structural polyprotein coding region of CHIKV. The
sequences obtained in this study are highlighted in bold. Numbers indicate bootstrap values for the groups to the right.
doi:10.1371/journal.pntd.0002483.g003
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cases per 1,000 persons per year (15.9% of febrile episodes) in the
same cohort in 2000 to 2002 [16] and our present findings show
that the corresponding incidence rate of chikungunya in these
years was 7.9 cases per 1,000 persons per year (6.9% of febrile
episodes). In 2004 and 2008, the incidence rates for chikungunya
were in the same range as those for dengue (data not shown).The
overall prevalence of CHIK between August 2000 to June 2004
and September 2006 to April 2008 was 7.1% of febrile episodes,
and the overall incidence rate during this time frame was 10.1
cases per 1,000 persons per year.
Another finding of our study was that chikungunya infections
were generally mild and of short duration. Only two-thirds of cases
requested medical leave from work, with most only requesting 2–3
days of leave. The percentage of chikungunya cases in our study
that were hospitalized was significantly lower than for the dengue
cases detected in our study (unpublished data). Additionally,
during the first phase of our study, when data on arthralgia was
not specifically asked, only 38.9% of volunteers reported it as a
chief or other complaint, suggesting this symptom was minor or
absent. Also, we did not find volunteers with prolonged illness or
complications. Similar to our clinical findings, mild chikungunya
cases were also reported among young migrant workers in
Singapore during a 2008 outbreak [22]. This is in contrast to
what was reported in previous outbreaks where debilitating
arthralgia was a frequent symptom in acute disease, sometimes
persisting for months to even years [23–25] and in the recent La
Reunion and India outbreaks where severe disease with neuro-
logical involvement was also reported [26,27].
Genotyping of the CHIKV in twenty patients showed that
infections were caused by the Asian genotype and not the ECSA
genotype, which was responsible for the 2005 outbreak in the
Indian Ocean and has since then spread to India and Southeast
Asia, causing unprecedented nationwide outbreaks in Malaysia,
Singapore and Thailand [7]. The detection of the ECSA genotype
has not been reported in Indonesia and the Asian genotype was
the only genotype identified in Taiwan travelers returning from
Indonesia in 2007–2008 [28] and in hospitalized patients in
Surabaya in 2011 [15]. As ECSA genotype has been detected
elsewhere in Southeast Asia [18,29–31], this genotype may have
circulated in Indonesia as well, but remains unidentified as routine
chikungunya surveillance has not been established. Still little is
known about differences in clinical presentation and epidemiology
between infections caused by the Asian and the ECSA genotype.
Our findings suggest that the illness caused by this Asian genotype
is often relatively mild and that infections occur year round in
Bandung, Indonesia. Interestingly, infections by the same Asian
genotype that were reported in travelers returning from Indonesia
[32] and during outbreaks in Indonesia [11,17] appear to be
associated with more severe disease. Selection bias, whereby
chikungunya was only considered in those with more severe
disease, and differences in the CHIKV strains that circulate during
the inter-epidemic period and those causing outbreaks and/or
severe illness might explain these differences. Another plausible
Table 1. Signs, symptoms and laboratory results for CHIK
cases.
Symptoms N % Pos
Myalgia 124/134 92.5
Headache 119/134 88.8
Arthralgia
1st phase 37/95 38.9
2nd phase 34/39 87.2
Nausea 71/134 53.0
Retro-orbital pain 51/134 38.1
Cough 37/134 27.6
Abdominal Pain 33/134 24.6
Sore throat 31/134 23.1
Coryza 31/134 23.1
Rash 17/134 12.7
Vomiting 15/134 11.2
Diarrhea 14/134 10.4
Leukopenia(,4000/mm3) 20/134 14.9
Thrombocytopenia (,150,000/mm3) 15/134 11.2
doi:10.1371/journal.pntd.0002483.t001
Table 2. Lab results for possible recurrent CHIKV infections.
ID Number First infection Second infection
Date of illness Lab results Date of illness Lab results
005-1411 unknown Pre-illness specimen 4 JAN2003 Positive RT-PCR and
(21 SEP 2002) Isolation
CHIKV IgM: 400 CHIKV IgM: 800 to 400
CHIK IgG: 800 CHIKV IgG: 6400 to 6400
005-2048 unknown Pre-illness specimen 6 MAR2001 Positive RT-PCR
(25 NOV2000) CHIKV IgM: 100 to 400
CHIKV IgM: 400 CHIKV IgG: 3200 to 6400
CHIK IgG: 800
005-1449 11 JUN 2002 Positive RT-PCR and 19 DEC2006 Negative RT-PCR and
Isolation Isolation
CHIKV IgM: neg to 6400 CHIKV IgM: 400–1600
CHIKV IgG: neg to 100 CHIKV IgG: 1600–6400
doi:10.1371/journal.pntd.0002483.t002
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explanation of mostly mild cases in our study was the young adult
population in contrast to children or the elderly who commonly
experience severe illness [33–35].
According to our literature review, CHIKV infections have
commonly been associated with outbreaks [7] and many countries
reported a long hiatus between outbreaks, for example 32 years in
India, 15 years in Indonesia and 7 years in Malaysia [11,36,37].
To the best of our knowledge, our study is the first to report year
round CHIKV infections over several years. As such, it provides a
better understanding of how CHIKV is maintained in the
population. It was speculated that unreported infections were also
the cause of an outbreak in Malaysia in 2006 [36]. One of the
reasons chikungunya is not reported is the difficulty in distin-
guishing chikungunya clinically from other infections, such as
dengue [2,38]. This may be especially challenging when arthral-
gia, which is considered a pathognomonic symptom of chikungu-
nya, is not a prominent clinical feature. Moreover, chikungunya is
generally perceived to occur only in outbreaks [39]. The limited
sensitivity of currently available rapid diagnostic tests for
chikungunya and the long persistence of CHIKV IgM antibodies
may further complicate the correct diagnosis of chikungunya
[14,40]. Advanced diagnostic tools such as virus isolation and RT-
PCR are generally only available in large hospitals or research
institutions. In our study, chikungunya cases were identified almost
every month throughout the year from 2001–2004 and 2006–
2008. The peak of chikungunya cases was during or after the
monsoon season when the population of Aedes aegypti is abundant.
This finding is consistent with previous reports from other
countries [41–43]. In addition, acute chikungunya infections were
still detected, albeit at a lower frequency, during the dry season,
suggesting that virus transmission was maintained during this
period. This is not surprising as Aedes aegypti and albopictus were
found abundantly in Bandung and elsewhere in Indonesia
throughout the year despite extensive eradication efforts [11,44–
47]. Based on the data from this study, we did not observe any
clustering or focused geographical transmission (data not shown).
One of the powerful features of our prospective cohort study
was that volunteers were followed for several years. Therefore, we
were able to observe the kinetics of CHIKV IgM and IgG
antibodies longitudinally after infection. Our finding that IgM
antibodies could be detected beyond one year was consistent with
previous reports [41,48]. In a returning traveler from La Reunion
Island, IgM antibodies remained detectable after two years and
this was associated with persistent arthralgia [48]. In our study,
among nine patients observed, IgM antibodies disappeared
between five months and 19 months (median of 10 months) after
infection. Post-illness sera were collected during programmed
serosurveys and not related to any febrile episodes, arguing against
the possibility that the high titers of anti-CHIKV antibodies were
induced by a nonspecific polyclonal activation after unrelated
infections.
Persistence of IgM antibodies also has consequences for
diagnostics. In the absence of virus culture or RT-PCR, IgM
and IgG serology assays should be conducted using paired sera
collected at least 10 days apart to confirm the increasing titers. We
also identified three patients (2%) with symptomatic CHIKV
infections with laboratory features suggestive of possible secondary
chikungunya infection, which, to our knowledge, has not yet been
reported. Indeed, the current dogma holds that CHIKV infection
will provide life-long immunity [49]. In one of these three patients,
the RT-PCR for CHIKV was negative and the diagnosis of an
acute chikungunya infection was based on a rapid increase in both
IgM and IgG. This rapid increase in IgM and IgG, which also
may have resulted in rapid virus clearance, was different from the
kinetics of IgM and IgG antibodies during primary infections. IgM
antibodies in primary infections were often not detected in acute
sera or only identified in low titers, followed by a rapid increase
during convalescence, when IgG antibodies first became detect-
able. We could not perform sequence analysis to identify the
differences between CHIKV isolates in primary and secondary
infections because, in two cases, the first infections occurred prior
to their participation in this study while in the third case, CHIKV
could be isolated only from the first infection. Cross-reactivity with
viruses belonging to the Semliki group is a potential explanation.
However, Ross River and O’nyong nyong viruses have never been
reported in Indonesia and our CHIKV IgM immunoassay does
not show immunoreactivity with the Ross River virus [17]. In the
absence of virological data from human cases or mosquitoes due to
the scarcity of chikungunya research in Indonesia, we speculate
that these three patients in Bandung were re-infected by different
CHIKV strains. Further studies are needed to confirm this
hypothesis, including close longitudinal observation of those who
experienced first CHIKV infections and performance of plaque
reduction neutralization tests, which were not available in our
laboratory due to the BSL-3 containment requirement.
Our study has some limitations. First, data on arthralgia as a
symptom during the first phase of the study was collected based on
passive reports from patients during their visits. On the other
hand, it may also provide us some information regarding the
percentage of patients who consider arthralgia as a prominent
symptom. Listing arthralgia as one of the subjective symptoms that
should be routinely included in questionnaires during acute illness
may unintentionally increase the likelihood of subjects endorsing
this symptom. Second, as mentioned above, the diagnosis of
previous infections in two cases and recurrent infection in one case
was based solely on results obtained by ELISA. Detecting the
presence of virus either by tissue culture isolation or RT-PCR, or
performing plaque reduction neutralization assays on the serum
samples would have provided more definitive evidence for
recurrent infections
In conclusion, our findings provide an estimate of the disease
burden of CHIKV infections in Bandung, Indonesia and
especially provide new information on its endemic transmission
during inter-epidemic periods. These data highlight the impor-
tance of considering chikungunya in the differential diagnoses of
acute febrile illnesses. Further studies are required to determine
the significance of persistent IgM antibodies and the relation to
arthralgia, the possibility of repeat CHIKV infections and the
differences between strains in their potential to cause severe illness
and epidemic versus endemic transmission. In addition, national
surveillance needs to be established to monitor for the possible
introduction of the ECSA genotype into Indonesia, as the
transmission of this genotype may have a greater impact on
public health. Finally, our findings highlight the need for
development of affordable and sensitive rapid antigen diagnostic
tests for early diagnosis of CHIKV infections and the need for a
vaccine, especially since vector control has been unsuccessful so
far.
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